Cargando…

Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial

Gait and balance disturbances typically emerge in advanced Parkinson’s disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Daniel, Walach, Margarete, Meisner, Christoph, Fritz, Melanie, Scholten, Marlieke, Breit, Sorin, Plewnia, Christian, Bender, Benjamin, Gharabaghi, Alireza, Wächter, Tobias, Krüger, Rejko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692032/
https://www.ncbi.nlm.nih.gov/pubmed/23757762
http://dx.doi.org/10.1093/brain/awt122
_version_ 1782274554892124160
author Weiss, Daniel
Walach, Margarete
Meisner, Christoph
Fritz, Melanie
Scholten, Marlieke
Breit, Sorin
Plewnia, Christian
Bender, Benjamin
Gharabaghi, Alireza
Wächter, Tobias
Krüger, Rejko
author_facet Weiss, Daniel
Walach, Margarete
Meisner, Christoph
Fritz, Melanie
Scholten, Marlieke
Breit, Sorin
Plewnia, Christian
Bender, Benjamin
Gharabaghi, Alireza
Wächter, Tobias
Krüger, Rejko
author_sort Weiss, Daniel
collection PubMed
description Gait and balance disturbances typically emerge in advanced Parkinson’s disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulation on caudal contacts of a subthalamic lead. Here, we hypothesized that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata improves axial symptoms compared with standard subthalamic nucleus stimulation. Twelve patients were enrolled in this 2 × 2 cross-over double-blind randomized controlled clinical trial and both the safety and efficacy of combined subthalamic nucleus and substantia nigra pars reticulata stimulation were evaluated compared with standard subthalamic nucleus stimulation. The primary outcome measure was the change of a broad-scaled cumulative axial Unified Parkinson’s Disease Rating Scale score (Scale II items 13–15, Scale III items 27–31) at ‘3-week follow-up’. Secondary outcome measures specifically addressed freezing of gait, balance, quality of life, non-motor symptoms and neuropsychiatric symptoms. For the primary outcome measure no statistically significant improvement was observed for combined subthalamic nucleus and substantia nigra pars reticulata stimulation at the ‘3-week follow-up’. The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged. The combined stimulation of subthalamic nucleus and substantia nigra pars reticulata was safe, and of note, no clinically relevant neuropsychiatric adverse effect was observed. Patients treated with subthalamic nucleus and substantia nigra pars reticulata stimulation revealed no ‘global’ effect on axial motor domains. However, this study opens the perspective that concomittant stimulation of the substantia nigra pars reticulata possibly improves otherwise resistant freezing of gait and, therefore, highly warrants a subsequent phase III randomized controlled trial.
format Online
Article
Text
id pubmed-3692032
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-36920322013-06-25 Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial Weiss, Daniel Walach, Margarete Meisner, Christoph Fritz, Melanie Scholten, Marlieke Breit, Sorin Plewnia, Christian Bender, Benjamin Gharabaghi, Alireza Wächter, Tobias Krüger, Rejko Brain Original Articles Gait and balance disturbances typically emerge in advanced Parkinson’s disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulation on caudal contacts of a subthalamic lead. Here, we hypothesized that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata improves axial symptoms compared with standard subthalamic nucleus stimulation. Twelve patients were enrolled in this 2 × 2 cross-over double-blind randomized controlled clinical trial and both the safety and efficacy of combined subthalamic nucleus and substantia nigra pars reticulata stimulation were evaluated compared with standard subthalamic nucleus stimulation. The primary outcome measure was the change of a broad-scaled cumulative axial Unified Parkinson’s Disease Rating Scale score (Scale II items 13–15, Scale III items 27–31) at ‘3-week follow-up’. Secondary outcome measures specifically addressed freezing of gait, balance, quality of life, non-motor symptoms and neuropsychiatric symptoms. For the primary outcome measure no statistically significant improvement was observed for combined subthalamic nucleus and substantia nigra pars reticulata stimulation at the ‘3-week follow-up’. The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged. The combined stimulation of subthalamic nucleus and substantia nigra pars reticulata was safe, and of note, no clinically relevant neuropsychiatric adverse effect was observed. Patients treated with subthalamic nucleus and substantia nigra pars reticulata stimulation revealed no ‘global’ effect on axial motor domains. However, this study opens the perspective that concomittant stimulation of the substantia nigra pars reticulata possibly improves otherwise resistant freezing of gait and, therefore, highly warrants a subsequent phase III randomized controlled trial. Oxford University Press 2013-07 2013-06-11 /pmc/articles/PMC3692032/ /pubmed/23757762 http://dx.doi.org/10.1093/brain/awt122 Text en © The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Weiss, Daniel
Walach, Margarete
Meisner, Christoph
Fritz, Melanie
Scholten, Marlieke
Breit, Sorin
Plewnia, Christian
Bender, Benjamin
Gharabaghi, Alireza
Wächter, Tobias
Krüger, Rejko
Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
title Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
title_full Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
title_fullStr Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
title_full_unstemmed Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
title_short Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial
title_sort nigral stimulation for resistant axial motor impairment in parkinson’s disease? a randomized controlled trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692032/
https://www.ncbi.nlm.nih.gov/pubmed/23757762
http://dx.doi.org/10.1093/brain/awt122
work_keys_str_mv AT weissdaniel nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT walachmargarete nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT meisnerchristoph nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT fritzmelanie nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT scholtenmarlieke nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT breitsorin nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT plewniachristian nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT benderbenjamin nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT gharabaghialireza nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT wachtertobias nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial
AT krugerrejko nigralstimulationforresistantaxialmotorimpairmentinparkinsonsdiseasearandomizedcontrolledtrial